KeyBanc analyst Donald Hooker raised his price target for Charles River to $162 from $151 after hosting a series of investor meetings with the company. Hooker tells investors in a research note that the upwardly revised price target reflects ongoing strong biopharma demand and current CRO average trading multiples, saying Charles River should "comfortably" generate high single-digit revenue growth and low teens EBITDA growth, on an organic basis, while maintaining capital spending below 7% revenues. The analyst keeps an Overweight rating on the shares.